Stocks & Investing
Stocks and Investing
Stocks and Investing
Thu, December 22, 2022
[ Thu, Dec 22nd 2022
] - WOPRAI
[ Thu, Dec 22nd 2022
] - WOPRAI
[ Thu, Dec 22nd 2022
] - WOPRAI
[ Thu, Dec 22nd 2022
] - WOPRAI
[ Thu, Dec 22nd 2022
] - WOPRAI
[ Thu, Dec 22nd 2022
] - WOPRAI
[ Thu, Dec 22nd 2022
] - WOPRAI
[ Thu, Dec 22nd 2022
] - WOPRAI
[ Thu, Dec 22nd 2022
] - WOPRAI
[ Thu, Dec 22nd 2022
] - WOPRAI
[ Thu, Dec 22nd 2022
] - WOPRAI
[ Thu, Dec 22nd 2022
] - WOPRAI
[ Thu, Dec 22nd 2022
] - WOPRAI
Wed, December 21, 2022
[ Wed, Dec 21st 2022
] - WOPRAI
[ Wed, Dec 21st 2022
] - WOPRAI
[ Wed, Dec 21st 2022
] - WOPRAI
[ Wed, Dec 21st 2022
] - WOPRAI
[ Wed, Dec 21st 2022
] - WOPRAI
[ Wed, Dec 21st 2022
] - WOPRAI
[ Wed, Dec 21st 2022
] - WOPRAI
[ Wed, Dec 21st 2022
] - WOPRAI
[ Wed, Dec 21st 2022
] - WOPRAI
[ Wed, Dec 21st 2022
] - WOPRAI
[ Wed, Dec 21st 2022
] - WOPRAI
[ Wed, Dec 21st 2022
] - WOPRAI
Matthew Barcus Initiated (XLO) at Strong Buy and Held Target at $7 on, Dec 21st, 2022
Matthew Barcus of Chardan Capital, Initiated "Xilio Therapeutics, Inc." (XLO) at Strong Buy and Held Target at $7 on, Dec 21st, 2022.
Matthew has made no other calls on XLO in the last 4 months.
There is 1 other peer that has a rating on XLO. Out of the 1 peers that are also analyzing XLO, 0 agree with Matthew's Rating of Hold.
This is the rating of the analyst that currently disagrees with Matthew
- Dane Leone of "Raymond James" Maintained at Buy with Decreased Target to $13 on, Thursday, November 10th, 2022
